An Open-Label Extension Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis

Investigator: Sheetal Shroff, MD

Study Coordinator:

Status: Open Not Enrolling Number: NCT04650854


Protocol Number: PRO00029194


The purpose of this study is to assess the safety, tolerability and efficacy of additional 6-week treatment cycles with rozanolixizumab in study participants with generalized myasthenia gravis (gMG).
More to Explore